The stock of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has seen a 12.85% increase in the past week, with a -0.45% drop in the past month, and a -5.13% decrease in the past quarter. The volatility ratio for the week is 5.11%, and the volatility levels for the past 30 days are at 3.99% for TEVA. The simple moving average for the past 20 days is 1.78% for TEVA’s stock, with a -7.19% simple moving average for the past 200 days.
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
The stock has a 36-month beta value of 0.69. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TEVA is 1.15B, and at present, short sellers hold a 2.43% of that float. On March 17, 2025, the average trading volume of TEVA was 13.28M shares.
TEVA) stock’s latest price update
The stock of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) has increased by 1.38 when compared to last closing price of 16.33.Despite this, the company has seen a gain of 12.85% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-12 that Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Leerink’s 2025 Global Healthcare Conference March 12, 2025 8:40 AM ET Company Participants Richard Francis – CEO Unidentified Company Representative Hi. Good morning, everybody.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Argus repeating the rating for TEVA by listing it as a “Buy.” The predicted price for TEVA in the upcoming period, according to Argus is $20 based on the research report published on July 10, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $14. The rating they have provided for TEVA stocks is “Neutral” according to the report published on March 08th, 2024.
Piper Sandler gave a rating of “Overweight” to TEVA, setting the target price at $19 in the report published on February 12th of the previous year.
TEVA Trading at -9.34% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.39% of loss for the given period.
Volatility was left at 3.99%, however, over the last 30 days, the volatility rate increased by 5.11%, as shares surge +1.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.27% lower at present.
During the last 5 trading sessions, TEVA rose by +12.27%, which changed the moving average for the period of 200-days by -1.73% in comparison to the 20-day moving average, which settled at $16.26. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw -24.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Daniell Richard, who sale 70,961 shares at the price of $15.91 back on Mar 05 ’25. After this action, Daniell Richard now owns 48,384 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $1,128,642 using the latest closing price.
Hughes Eric A, the See “Remarks” of Teva- Pharmaceutical Industries Ltd. ADR, sale 15,174 shares at $15.73 during a trade that took place back on Mar 04 ’25, which means that Hughes Eric A is holding 8,077 shares at $238,757 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.49 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.1. The total capital return value is set at -0.01. Equity return is now at value -25.44, with -3.96 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 3.36. The interest coverage ratio of the stock is -0.3.
Currently, EBITDA for the company is -303.0 million with net debt to EBITDA at 19.02. When we switch over and look at the enterprise to sales, we see a ratio of 2.04. The receivables turnover for the company is 5.41for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.98.
Conclusion
To sum up, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
